Alfatradiol (0.025%) - An effective and safe therapy for the treatment of androgenetic alopecia in women and men;Alfatradiol (0,025%) - Eine wirksame und sichere therapieoption zur behandlung der androgenetischen alopezie bei frauen und männern

Aktuelle Dermatologie

Volumn 31, Issue 12, 2005, Pages 553-560

  Wozel, G ^a   Narayanan, S ^b   Jackel A ^b   Lutz, G A ^c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Galderma Laboratorium GmbH   (Germany)

^c Hair and Nail   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ESTRADIOL; HORMONE ANALOG; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALOPECIA; ANALYTIC METHOD; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ELL CRANELL; FEMALE; HAIR GROWTH; HORMONE ACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; SAMPLE SIZE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 29244476536     PISSN: 03402541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-870188     Document Type: Article

References (48)

1. Norwood OT. Male-Pattern baldness. Classification and incidence. South Med J. 1975; 68:1359-1370
2. Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg 2001;27:53-54
3. Orfanos CE. Androgenetic Alopecia: Clinical Aspects and Treatment. In: Orfanos CE, Happle R (eds). Hair and Hair Diseases. Berlin Heidelberg New York: Springer, 1990
4. Price VH. Androgenetic alopecia in women. J Investig Dermatol Symp Proc 2003;8:24-27
5. Severi G, Sinclair R, Hopper JL, English DR, McCredie MR, Boyle P, Giles GG. Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors. Br J Dermatol. 2003;149:1207-1213
6. Venning VA, Dawber RP. Patterned androgenic alopecia in women. J Am Acad Dermatol. 1988; 18:1073-1077
7. Paik JH, Yoon JB, Sim WY, Kim BS, Kim NI. The prevalence and types of androgenetic alopecia in Korean men and women. Br J Dermatol 2001; 145:95-99
8. Pathomvanich D, Pongratananukul S, Thienthaworn P, Manoshai S. A random study of Asian male androgenetic alopecia in Bangkok, Thailand. Dermatol Surg 2002;28: 804-807
9. Tang PH, Chia HP, Cheong LL, Koh D. A community study of male androgenetic alopecia in Bishan, Singapore. Singapore Med J 2000;41: 202-205
10. Braun-Falco O, Heilgemeir GP. Aussagewert der Haarwurzelstatusmethode. Hautarzt 1977;28:136-139
11. Cash T. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol 1992; 26:926-931
12. Girman CJ, Hartmaier S, Roberts J, Bergfeld W, Waldstreicher J. Patient-perceived importance of negative effects of androgenetic alopecia in women. J Womens Health Gend Based Med 1999;8:1091-1095
13. Hadshiew IM, Foitzik K, Arck PC, Paus R. Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia. J Invest Dermatol 2004; 123:455-457
14. Van der Donk J, Hunfeld AM, Passchier J, Knegt-Junk KJ, Nieboer C. Quality of life and maladjustment associated with hair loss in women with alopecia androgenetica. Soc Sci Med 1994;38:159-163
15. Van der Donk J, Passchier J, Knegt-Junk C, van der Wegen-Keijser MH, Nieboer C, Stolz E, Verhage F. Psychological characeristics of women with androgenetic alopecia: a controlled study. Br J Dermatol 1991; 125:248-252
16. Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on quality of life. J Eur Acad Dermatol Venereol 2000; 15:137-139
17. Hamilton J. Patterned loss of hair in man; types and incidence. Ann NY Acad Sci 1951;53:708-714
18. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977;97: 247-254
19. Hoffmann R, Happle R. Current understanding of androgenetic alopecia. Part I: etiopathogenesis. Eur J Dermatol 2000;10:319-327
20. Hoffmann R. Enzymology of the hair follicle. Eur J Dermatol 2001;11: 296-300
21. Hoffmann R. Androgenetische Alopezie beim Mann. Z Hautkr 2002; 77:333-341
22. Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol 2002;198: 89-95
23. Trueb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol 2002;37:981-990
24. Bläuer M, Vaalasti A, Pauli SL, Ylikomi T, Joensuu T, Tuohimaa P. Location of androgen receptor in human skin. J Invest Dermatol 1991;97: 264-268
25. Fiuraskova M, Kucerova R, Kolar Z. Pathobiology of androgenetic alopecia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003; 147:37-41
26. Hanneken S, Ritzmann S, Nothen MM, Kruse R. Androgenetic alopecia. Current aspects of a common phenotype. Hautarzt 2003;54:703-712
27. Harris G, Azzolina B, Baginsky W, Cimis G, Rasmusson GH, Tolman RL, Raetz CRH, Ellsworth K. Identification and selective inhibition of an isoenzyme of steroid α-reductase in human scalp. Proc Natl Acad Sci USA 1992;89:10787-10791
28. Hoffmann R, Niiyama S, Huth A, Kissling S, Happle R. 17alpha-estradiol induces aromatase activity in intact human anagen hair follicles ex vivo. Exp Dermatol 2002;11:376-380
29. Sawaya ME, Hordinsky MK. The antiandrogens. When and how they should be used. Dermatol Clin. 1993;11:65-72
30. Tosti A, Camacho-Martinez F, Dawber R. Management of androgenetic alopecia. J Eur Acad Dermatol Venereol 1999; 12:5-14
31. Sawaya ME, Price VH. Different levels of 5α-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997;109:296-300
32. Goss PE, Clark RM, Ambus U, Weizel HA, Wadden NA, Crump M, Walde D, Tye LM, De Coster R, Bruynseels J. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clin Cancer Res 1995;1:287-294
33. Chen W, Zouboulis CC, Orfanos CE. The 5α-reductase system and its inhibitors. Dermatology 1996;193:177-184
34. Hoffmann R, Happle R. Die pathogenetische Bedeutung der 5α-Reduktase-Isoenzyme für die androgenetische Alopezie. Hautarzt 1999; 50:165-173
35. Hevert F. 17α-Estradiol - ein moderner Inhibitor der 5α-Reductase. In: A. Plettenberg, Meigel WN, Moll I (eds). Dermatologie an der Schwelle zum neuen Jahrtausend. Berlin Heidelberg New York: Springer, 2000
36. Meyer WJ, Henneman DH, Keiser HR, Bartter FC 17 alpha estradiol: separation of estrogen effect on collagen from other clinical and biochemical effects in man. Res Commun Chem Pathol Pharmacol 1976;13: 685-695
37. Schriefers H, Wright MC, Rozman T, Hevert F. Hemmung des Testosteron-Stoffwechsels durch 17α-Estradiol in Rattenleberschnitten. Arzneimittelforschung/Drug Res 1991;41: 1186-1189
38. Foley CL, Kirby RS. 5 alpha-reductase inhibitors: what's new? Curr Opin Urol 2003;13:31-37
39. Kiesewetter F, Schell H. Wirksamkeit von 17α-Estradiol in der Therapie der Alopecia androgenetica. (persönliche Mitteilung)
40. Orfanos CE, Vogels L Lokaltherapie der Alopecia androgenetica mit 17α-Estradiol-Östradiol. Dermatologica 1980;161:124-132
41. Sperling LC. Hair anatomy for the clinician. J Am Acad Dermatol 1991; 25:1-17
42. Witzel M, Braun-Falco O. Über den Haarwurzelstatus am menschlichen Capillitium unter physiologischen Bedingungen. Arch klin exp Derm 1963; 216: 221-230
43. Korge B. New and established methods for diagnosing hair diseases. Hautarzt 2003;54:699-702
44. Hoffmann R. TrichoScan. A new instrument for digital hair analysis. Hautarzt 2002;53:798-804
45. Randall VA, Ebling FJG. Seasonal changes in human hair growth. Br J Dermatol 1991; 124:146-151
46. Wolff H, Kunte C. Die Behandlung der androgenetischen Alopezie des Mannes mittels systemischer 5α-Reduktase-Hemmung. Hautarzt 1998;49:813-817
47. Cash T. Psychological effects of androgenetic alopecia on women: comparison with balding men and with female control subjects. J Am Acad Dermatol 1993;29:568-575
48. Imperato-McGinley J, Binienda Z, Arthur A, Minenberg D, Vaughan ED, Quimby F. The development of male pseudohermaphroditic rat using an inhibitor of the enzyme 5α-reductase. Endocrinol 1986;113:569-573